A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients
Yıl: 2022 Cilt: 52 Sayı: 4 Sayfa Aralığı: 1299 - 1310 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5436 İndeks Tarihi: 26-12-2022
A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients
Öz: Background/aim: Metabolomics has the potential to provide putative biomarkers and insights into the pathophysiology and diagnosis of pediatric multiple sclerosis (pMS), which is an inflammatory demyelinating disorder of the central nervous system with a broad spectrum of clinical manifestations. In this study, we aimed to investigate serum metabolomics in pMS to help elucidate the pathophysiology of MS. Materials and methods: An untargeted approach was applied using the quadrupole time-of-flight liquid chromatography/mass spectrometry (Q-TOF LC/MS) method to study plasma metabolites in patients with pMS (n = 33), patients with unclassified central nervous system demyelinating diseases (n = 6), and age-matched healthy control subjects (n = 40). The patient and control groups were compared for metabolites and the normalized peak areas differed statistically (p < 0.05), showing at least a 1.25-fold change between groups. Bioinformatic tools combined with a clinical perspective were employed for the identification of the putative metabolites. In addition to the untargeted metabolomics approach, targeted LC-MS/MS metabolite analysis was employed to compare the pMS group with the control group. Results: Significant differences between the patient and control groups were noted for tyramine, 4-hydroxyphenylacetaldehyde, sphingosine/3-dehydrosphinganine, prostaglandins/thromboxane A2, 20-hydroxy-leukotriene E4, 3α,7α,12α-trihydroxy-5β-cholestan- 26-al/calcitriol, pantetheine, ketoleucine/3-methyl-2-oxovaleric acid, L-arginine/D-arginine, coproporphyrinogen III, (S)-reticuline, carnosine, cytidine, and phosphoribosyl pyrophosphate. Additional tests for sphingosine 1-phosphate, sphingophosphocholines, ceramides, oxysterols, and calcitriol levels yielded significant metabolomic differences for the pMS group compared to the control group. The metabolomic data of 3/6 patients with unclassified demyelinating disorders matched the pMS group; their follow-up verified the diagnosis of pMS. Conclusion: In general, plasma metabolites related to sphingolipid metabolism, myelin products, inflammatory pathways, mitochondrial dysfunction, and oxidative stress were found to be altered in cases of pMS. The method applied in this study, combining untargeted analysis with a targeted approach, can be applied to larger series of cases of pMS and other demyelinating disorders for further validation.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M et al. Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. The Lancet Neurology 2014; 13 (9): 936-948. https://doi.org/10.1016/ s1474-4422(14)70093-6
- 2. Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Multiple Sclerosis Journal 2013; 19 (10): 1261- 1267. https://doi.org/10.1177/1352458513484547
- 3. Wishart DS, Feunang YD, Marcu A, Guo AC, Liang K et al. HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Research 2018; 46 (1): 608-617. https://doi.org/10.1093/ nar/gkx1089
- 4. Chong J, Wishart DS, Xia J. Using MetaboAnalyst 4.0 for comprehensive and integrative metabolomics data analysis. Current Protocols in Bioinformatics 2019; 68 (1): 86. https:// doi.org/10.1002/cpbi.86
- 5. Tulun Y. Investigation of plasma metabolomic biomarkers of childhood multiple sclerosis. MD, Hacettepe University, Ankara, Türkiye, 2019.
- 6. Kaplan O, Çelebier M. Evaluation of Recent Data Processing Strategies on Q-TOF LC/MS Based Untargeted Metabolomics. Mass Spectrometry Letters 2020; 11 (1): 1-5. http://dx.doi. org/10.5478/MSL.2020.11.1.1
- 7. Libiseller G, Dvorzak M, Kleb U, Gander E, Eisenberg T et al. IPO: a tool for automated optimization of XCMS parameters. BioMed Central Bioinformatics 2015; 16 (1): 118. https://doi. org/10.1186/s12859-015-0562-8
- 8. Aslan M, Kıraç E, Kaya S, Özcan F, Salim O et al. Decreased Serum Levels of Sphingomyelins and Ceramides in Sickle Cell Disease Patients. Lipids 2018; 53 (3): 313-322. https://doi. org/10.1002/lipd.12027
- 9. Jiang X, Sidhu R, Porter FD, Yanjanin NM, Speak AO et al. A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma. Journal of Lipid Research 2011; 52 (7): 1435-1445. https://doi. org/10.1194/jlr.D015735
- 10. Jurynczyk M, Probert F, Yeo T, Tackley G, Claridge TDW et al. Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG- antibody disease. Acta Neuropathologica Communications 2017; 5 (1): 95. https://doi.org/10.1186/s40478-017-0495-8
- 11. Yeo T, Probert F, Jurynczyk M, Sealey M, Cavey A et al. Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling. Neurology- Neuroimmunology & Neuroinflammation 2019; 6 (6): 626. https://doi.org/10.1212/NXI.0000000000000626
- 12. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine- 1-phosphate signaling and its role in disease. Trends in Cell Biology 2012; 22 (1): 50-60. https://doi.org/10.1016/j. tcb.2011.09.003
- 13. Ward S, Page MI, McHugh P, Powles NT. Sphingosine and dihydrosphingosine as biomarkers for multiple sclerosis identified by metabolomic profiling using coupled UPLC- MS. Analytical Methods 2017; 9 (41): 5929-5934. https://doi. org/10.1039/C7AY01922J
- 14. Kurz J, Brunkhorst R, Foerch C, Blum L, Henke M et al. The relevance of ceramides and their synthesizing enzymes for multiple sclerosis. Clinical Science 2018; 132 (17): 1963-1976. https://doi.org/10.1042/cs20180506
- 15. Cosentino M, Marino F. Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks? Journal of Neuroimmune Pharmacology 2013; 8 (1): 163-179. https://doi.org/10.1007/s11481-012-9410-z
- 16. Nemazannikova N, Mikkelsen K, Stojanovska L, Blatch GL, Apostolopoulos V. Is there a Link between Vitamin B and Multiple Sclerosis? Medicinal Chemistry 2018; 14 (2): 170-180. https://doi.org/10.2174/1573406413666170906123857
- 17. Mathur D, López-Rodas G, Casanova B, Marti MB. Perturbed glucose metabolism: insights into multiple sclerosis pathogenesis. Frontiers in Neurology 2014; 5: 250. https://doi. org/10.3389/fneur.2014.00250
- 18. Bäck M, Yurdagul A, Tabas I, Öörni K, Kovanen PT. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nature Reviews. Cardiology 2019; 16 (7): 389- 406. https://doi.org/10.1038/s41569-019-0169-2
- 19. Fiedler SE, Kerns AR, Tsang C, Tsang V, Bourdette D et al. Dimethyl fumarate activates the prostaglandin EP2 receptor and stimulates cAMP signaling in human peripheral blood mononuclear cells. Biochemical and Biophysical Research Communications 2016; 475 (1): 19-24. https://doi. org/10.1016/j.bbrc.2016.05.021
- 20. Morel A, Miller E, Bijak M, Saluk J. The increased level of COX- dependent arachidonic acid metabolism in blood platelets from secondary progressive multiple sclerosis patients. Molecular and Cellular Biochemistry 2016; 420 (1): 85-94. https://doi. org/10.1007/s11010-016-2770-6
- 21. Poeaknapo C, Schmidt J, Brandsch M, Dräger B, Zenk MH. Endogenous formation of morphine in human cells. Proceedings of the National Academy of Sciences 2004; 101 (39): 14091-14096. https://doi.org/10.1073/pnas.0405430101
- 22. Sharp BM. Multiple opioid receptors on immune cells modulate intracellular signaling. Brain, Behavior, and Immunity 2006; 20 (1): 9-14. https://doi.org/10.1016/j.bbi.2005.02.002
- 23. Brown N, Alkhayer K, Clements R, Singhal N, Gregory R et al. Neuronal hemoglobin expression and its relevance to multiple sclerosis neuropathology. Journal of Molecular Neuroscience 2016; 59 ( 1): 1-17. https://doi.org/10.1007/s12031-015-0711-6
- 24. Islam MT. Oxidative stress and mitochondrial dysfunction- linked neurodegenerative disorders. Neurological Research 2017; 39 (1): 73-82. https://doi.org/10.1080/01616412.2016.12 51711
- 25. Noga MJ, Dane A, Shi S, Attali A, van Aken H et al. Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis. Metabolomics 2012; 8 (2): 253-263. https://doi. org/10.1007/s11306-011-0306-3
- 26. LaNoue SHASK. 6 Branched Chain Amino Acids (BCAAs) in Brain. Handbook of Neurochemistry and Molecular Neurobiology: Amino Acids and Peptides in the Nervous System 2007.
- 27. Lan M, Tang X, Zhang J, Yao Z. Insights in pathogenesis of multiple sclerosis: nitric oxide may induce mitochondrial dysfunction of oligodendrocytes. Reviews in the Neurosciences 2018; 29 (1): 39-53. https://doi.org/10.1515/ revneuro-2017-0033
- 28. Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. The Lancet Neurology 2002; 1 (4): 232-241. https:// doi.org/10.1016/s1474-4422(02)00102-3
- 29. Sylvestre DA, Slupsky CM, Aviv RI, Swardfager W, Taha AY. Untargeted metabolomic analysis of plasma from relapsing- remitting multiple sclerosis patients reveals changes in metabolites associated with structural changes in brain. Brain Research 2020; 1732: 146589. https://doi.org/10.1016/j. brainres.2019.146589
- 30. Caruso G, Caraci F, Jolivet RB. Pivotal role of carnosine in the modulation of brain cells activity: Multimodal mechanism of action and therapeutic potential in neurodegenerative disorders. Progress in Neurobiology 2019; 175: 35-53. https:// doi.org/10.1016/j.pneurobio.2018.12.004
- 31. Bhargava P, Smith MD, Mische L, Harrington E, Fitzgerald KC et al. Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation. The Journal of Clinical Investigation 2020; 130 (7): 3467-3482. https://doi. org/10.1172/jci129401
- 32. McMillin M, DeMorrow S. Effects of bile acids on neurological function and disease. The Federation of American Societies of Experimental Biology Journal 2016; 30 (11): 3658-3668. https://doi.org/10.1096/fj.201600275R
- 33. McDowell T-Y, Amr S, Culpepper WJ, Langenberg P, Royal W et al. Sun exposure, vitamin D intake and progression to disability among veterans with progressive multiple sclerosis. Neuroepidemiology 2011; 37 (1): 52-57. https://doi. org/10.1159/000329258
- 34. Bagur MJ, Murcia MA, Jiménez-Monreal AM, Tur JA, Bibiloni MM et al. Influence of Diet in Multiple Sclerosis: A Systematic Review. Advances in Nutrition 2017; 8 (3): 463-472. https:// doi.org/10.3945/an.116.014191
- 35. Nourbakhsh B, Bhargava P, Tremlett H, Hart J, Graves J et al. Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course. Annals of Clinical and Translational Neurology 2018; 5 (10): 1211-1221. https://doi. org/10.1002/acn3.637
- 36 .Loy BD, Fling BW, Sage KM, Spain RI, Horak FB. Serum histidine is lower in fatigued women with multiple sclerosis. Fatigue: Biomedicine, Health & Behavior 2019; 7 (2): 69-80. https://doi.org/10.1080/21641846.2019.1611786
- 37. Burnstock G. An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration. Neuropharmacology 2016; 104: 4-17. https://doi.org/10.1016/j.neuropharm.2015.05.031
- 38. Hon G, Hassan M, van Rensburg SJ, Abel S, Marais DW et al. Immune cell membrane fatty acids and inflammatory marker, C-reactive protein, in patients with multiple sclerosis. British Journal of Nutrition 2009; 102 (9): 1334-1340. https://doi. org/10.1017/s0007114509382185
| APA | Solmaz I, KAPLAN O, Çelebier M, SİNİCİ LAY İ, Anlar B (2022). A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients. , 1299 - 1310. 10.55730/1300-0144.5436 |
| Chicago | Solmaz Ismail,KAPLAN OZAN,Çelebier Mustafa,SİNİCİ LAY İNCİLAY,Anlar Banu A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients. (2022): 1299 - 1310. 10.55730/1300-0144.5436 |
| MLA | Solmaz Ismail,KAPLAN OZAN,Çelebier Mustafa,SİNİCİ LAY İNCİLAY,Anlar Banu A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients. , 2022, ss.1299 - 1310. 10.55730/1300-0144.5436 |
| AMA | Solmaz I,KAPLAN O,Çelebier M,SİNİCİ LAY İ,Anlar B A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients. . 2022; 1299 - 1310. 10.55730/1300-0144.5436 |
| Vancouver | Solmaz I,KAPLAN O,Çelebier M,SİNİCİ LAY İ,Anlar B A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients. . 2022; 1299 - 1310. 10.55730/1300-0144.5436 |
| IEEE | Solmaz I,KAPLAN O,Çelebier M,SİNİCİ LAY İ,Anlar B "A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients." , ss.1299 - 1310, 2022. 10.55730/1300-0144.5436 |
| ISNAD | Solmaz, Ismail vd. "A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients". (2022), 1299-1310. https://doi.org/10.55730/1300-0144.5436 |
| APA | Solmaz I, KAPLAN O, Çelebier M, SİNİCİ LAY İ, Anlar B (2022). A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients. Turkish Journal of Medical Sciences, 52(4), 1299 - 1310. 10.55730/1300-0144.5436 |
| Chicago | Solmaz Ismail,KAPLAN OZAN,Çelebier Mustafa,SİNİCİ LAY İNCİLAY,Anlar Banu A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients. Turkish Journal of Medical Sciences 52, no.4 (2022): 1299 - 1310. 10.55730/1300-0144.5436 |
| MLA | Solmaz Ismail,KAPLAN OZAN,Çelebier Mustafa,SİNİCİ LAY İNCİLAY,Anlar Banu A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients. Turkish Journal of Medical Sciences, vol.52, no.4, 2022, ss.1299 - 1310. 10.55730/1300-0144.5436 |
| AMA | Solmaz I,KAPLAN O,Çelebier M,SİNİCİ LAY İ,Anlar B A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients. Turkish Journal of Medical Sciences. 2022; 52(4): 1299 - 1310. 10.55730/1300-0144.5436 |
| Vancouver | Solmaz I,KAPLAN O,Çelebier M,SİNİCİ LAY İ,Anlar B A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients. Turkish Journal of Medical Sciences. 2022; 52(4): 1299 - 1310. 10.55730/1300-0144.5436 |
| IEEE | Solmaz I,KAPLAN O,Çelebier M,SİNİCİ LAY İ,Anlar B "A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients." Turkish Journal of Medical Sciences, 52, ss.1299 - 1310, 2022. 10.55730/1300-0144.5436 |
| ISNAD | Solmaz, Ismail vd. "A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients". Turkish Journal of Medical Sciences 52/4 (2022), 1299-1310. https://doi.org/10.55730/1300-0144.5436 |
